Retrospective cohort analyzed FIB-4 and FIB-5 in 155 NSTE-ACS patients, indicating FIB-4 predicts outcomes better.
Key Points
FIB-4≥3.25 triples the risk of major adverse events in NSTE-ACS patients, highlighting its significance in prognostic assessment.
During follow-up, the composite end-point occurred in 64.5% of patients with high FIB-4, compared to 36.3% with low FIB-4 (p=0.006).
Multivariable logistic regression confirmed FIB-4≥3.25 as an independent predictor (adjusted OR 3.14), outperforming the FIB-5 score in risk assessment.
FIB-5 did not predict composite outcomes or individual components, indicating its limited utility compared to FIB-4.